Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06979453 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Study acronym: POETYK-PsO-Ped
StatusRecruiting
PhasePhase 3
Started2025-12-03
View on ClinicalTrials.gov ↗

Amendment history

2026-09-02
Study Status, Contacts/Locations v21
Study sites132 entries, revised
LocalC.S. InstitutionMott Clinical Research Center (CRC) Shandong Provincial Dermatology Hospital and Shandong Institute of Dermatology and Venereology Charité - 0095 Local Institution - 0265 Charité Universitaetsmedizin Berlin - Campus MitteBejnamin Franklin
2026-08-10
Study Status, Contacts/Locations v20
Trial sites expanded: 129 → 132 locations
2026-07-13
Study Status, Contacts/Locations v19
Study sites127→129
2026-06-17
Study Status, Contacts/Locations v18
Trial sites expanded: 123 → 127 locations
2026-05-26
Study Status, Contacts/Locations v17
Trial sites expanded: 120 → 123 locations
2026-04-28
Study Status, Contacts/Locations v16
Trial sites expanded: 116 → 120 locations
2026-03-23
Study Status, Contacts/Locations v15
Study sites114→116
2026-02-23
Study Status, Contacts/Locations v14
Study sites114 entries, revised
LocalCenter InstitutionFor Dermatology Clinical Research, Inc. The University of Hong Kong-Shenzhen Hospital The First People's Hospital of Hangzhou Fondazione Policlinico Universitario Agostino Gemelli IRCCS - 0090Università Cattolica del Sacro Cuore LocalLotus-Med Institution - 0226 Local Institution - 0224 Local Institution - 0237 Local Institution - 0249Tunari
2026-02-02
Study Status, Contacts/Locations, IPDSharing v13
Study sites111→114
2026-01-09
Study Status v12
Re-verified, no change to tracked fields
2026-01-08
Study Status, Contacts/Locations v11
Study sites100→111
2025-12-16
Study Status, Contacts/Locations v10
Study sites98→100
2025-12-04
Study Status, Contacts/Locations v9
Start dateestimated 2025-11-15→confirmed 2025-12-03
Study sites95→98
2025-11-11
Study Status, Contacts/Locations v8
Start date2025-10-25→2025-11-15
Study sites92→95
2025-10-21
Study Identification, Study Status, Contacts/Locations v7
Start date2025-09-25→2025-10-25
Study sites86→92
2025-09-22
Study Status, Contacts/Locations v6
Start date2025-08-26→2025-09-25
Study sites81→86
2025-08-26
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v5
Trial statusNot Yet Recruiting→Recruiting
Study sites71→81
2025-07-29
Study Status, Contacts/Locations v4
Study sites70→71
2025-07-14
Study Status, Contacts/Locations, References v3
Study sites65→70
2025-06-16
Study Status, Contacts/Locations v2
Study sites61→65
2025-05-28
Study Status, Contacts/Locations v1
Study sites58→61
2025-05-13
Original filing
The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis
Trial Details
NCT Number NCT06979453
Lead Sponsor Bristol-Myers Squibb
Conditions Plaque Psoriasis
Enrollment 366 participants
Start Date 2025-12-03
Primary Completion 2029-10-12 (estimated)
Study Completion 2034-08-12 (estimated)
Updated on ClinicalTrials.gov 2026-09-03